EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit
Executive Summary
Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.
You may also be interested in...
CymaBay Focused On PBC With Seladelpar, Wants Partner For NASH
With an FDA clinical hold lifted, CymaBay plans to initiate a new Phase III in primary biliary cholangitis early in 2021. It also hopes to partner the drug in NASH with a company developing a metabolic drug for the disease.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
CymaBay’s Stalled Seladelpar Back In Play For PBC
Weeks after lifting of an FDA clinical hold, CymaBay says it will resume development of its PPAR agonist in primary biliary cholangitis. It will initiate a new Phase III trial but also use data from a terminated Phase III study.